臨床試驗

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

NCT：NCT06246968 · RECRUITING

NCT IDNCT06246968

狀態RECRUITING

開始日期2024-01-29

完成時間2027-01-29

SponsorMemorial Sloan Kettering Cancer Center (OTHER)

First posted2024-02-07

Last updated2026-09-14

簡要摘要

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。